Global Lymphedema Diagnostics Market Report 2019: Lymphoscintigraphy is Rapidly Developing to Be the First-Line Imaging Modality for Lymphedema Diagnostics

DUBLIN, Nov. 5, 2019 /PRNewswire/ -- The "Lymphedema Diagnostics Market by Technology (Lymphoscintigraphy, MRI, Near IR Fluorescence Imaging, Ultrasound), Disease Type (Cancer, Inflammatory Diseases, Cardiovascular, Filariasis), End User (Hospitals, Diagnostic Centers) - Global Forecasts to 2024" report has been added to ResearchAndMarkets.com's offering.

The Global Lymphedema Diagnostics Market is Projected to Reach USD 35 Million by 2024 from USD 24 Million in 2019, at a CAGR of 7.4%.

This report studies the lymphedema diagnostics market based on technology, disease type, end-user, and region. The report also studies factors (such as drivers and restraints) affecting market growth. In addition, it analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions (and the respective countries in these regions).

The growing global prevalence of lymphedema and cancer; technological advancements in diagnostic imaging modalities; and increasing investments, funds, and grants by public-private organizations are the major factors driving the growth of this market. However, the high cost of diagnostic imaging systems, the short half-life of radiopharmaceuticals, the limited supply of helium, and the increasing adoption of refurbished diagnostic imaging systems are expected to restrain the growth of this market.

In 2018, GE Healthcare (US), Philips (Netherlands), and Siemens Healthineers (Germany) dominated the lymphedema diagnostics market.

Other prominent players in this market include Canon, Inc. (Japan), Shimadzu Corporation (Japan), Stryker Corporation (US), Fluoptics (France), United Imaging Healthcare Co., Ltd. (China), Hitachi, Ltd. (Japan), Esaote, SpA (Italy), Neusoft Corporation (China), Mindray Medical International, Ltd. (China), Mitaka USA, Inc. (US), Curadel, LLC (US), and ImpediMed Ltd. (Australia).

In order to sustain their dominance in the lymphedema diagnostics industry, a majority of the prominent players are focusing on increasing their geographical presence and strengthening their product portfolios by adopting the strategies of product launches, agreements, partnerships, and acquisitions.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Lymphedema Diagnostics: Market Overview
4.2 Regional Analysis: Market, By Disease Type (2019)
4.3 Market, By Technology, 2019 vs 2024 (USD Million)
4.4 Near-Infrared Fluorescence Imaging Market, By Type, 2019 vs 2024 (USD Million)
4.5 Market, By Country

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Global Prevalence of Lymphedema
5.2.1.2 Growing Global Prevalence of Cancer
5.2.1.3 Technological Advancements and Adoption of Newer Diagnostic Modalities
5.2.1.4 Increasing Investments, Funds, and Grants By Public-Private Organizations
5.2.2 Restraints
5.2.2.1 High Cost of Diagnostic Imaging Systems
5.2.2.2 Short Half-Life of Radiopharmaceuticals
5.2.2.3 Limited Supply of Helium
5.2.2.4 Increasing Adoption of Refurbished Diagnostic Imaging Systems
5.2.3 Opportunities
5.2.3.1 Emerging Countries
5.2.4 Challenges
5.2.4.1 Hospital Budget Cuts

6 Lymphedema Diagnostics Market, By Technology
6.1 Introduction
6.2 Lymphoscintigraphy
6.2.1 Lymphoscintigraphy is Rapidly Developing to Be the First-Line Imaging Modality for Lymphedema Diagnostics
6.3 Magnetic Resonance Imaging
6.3.1 Magnetic Resonance Imaging Finds Major Applications in Lymphedema Treatment Planning
6.4 Ultrasound Imaging
6.4.1 Ultrasound Imaging has the Potential to Determine Tissue Changes Consistent With Different Stages of Lymphedema
6.5 Computed Tomography
6.5.1 High Cost of Computed Tomography to Limit Market Growth
6.6 X-Ray Lymphography
6.6.1 Invasive Nature & Risk of Radiation Exposure are Expected to Hamper Market Growth
6.7 Bioimpedance Analysis
6.7.1 Lack of Awareness About Bioimpedance Analysis is Limiting the Growth of This Segment
6.8 Near-Infrared Fluorescence Imaging
6.8.1 ICG Lymphography
6.8.1.1 ICG Lymphography Offers A Powerful Tool for Efficiently Diagnosing Various Stages of Lymphedema
6.8.2 Fluorescein Sodium Microlymphangiography
6.8.2.1 Fluorescein Sodium Microlymphangiography is Limited to Visualizing Only Initial Capillaries

7 Lymphedema Diagnostics Market, By Disease Type
7.1 Introduction
7.2 Cancer
7.2.1 One in Three Cancer-Treated Patients Develop Lymphedema
7.3 Inflammatory Diseases
7.3.1 Growing Prevalence of Inflammatory Conditions to Drive Market Growth
7.4 Cardiovascular Disease
7.4.1 Growing Awareness About Early Disease Diagnosis to Drive the Adoption of Lymphedema Diagnostic Tools
7.5 Other Diseases

8 Lymphedema Diagnostics Market, By End User
8.1 Introduction
8.2 Hospitals
8.2.1 The Large Number of Lymphedema Diagnostic Procedures Performed in Hospitals to Drive Market Growth
8.3 Diagnostic Centers
8.3.1 Increasing Number of Private Imaging Centers to Support Market Growth
8.4 Research & Academic Institutes
8.4.1 Budgetary Restrictions of Researchers are Limiting the Adoption of High-End Lymphedema Diagnostic Technologies
8.5 Other End Users

9 Lymphedema Diagnostics Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 The US Dominated the North American Market in 2018
9.2.2 Canada
9.2.2.1 Dearth of Radiologists is Restricting Market Growth in Canada
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany Accounts for the Largest Share of the European Market
9.3.2 France
9.3.2.1 Uncertainties With Regard to the Pricing Strategy of Diagnostic Companies to Limit Market Growth in France to A Certain Extent
9.3.3 UK
9.3.3.1 Rising Diagnostic Imaging Procedural Volumes Indicate Strong Growth in the UK Market
9.3.4 RoE
9.4 Asia Pacific
9.4.1 China
9.4.1.1 Rising Disease Incidence, Increasing Procedural Volumes, and Growth in the Geriatric Population have Contributed to Market Growth in China
9.4.2 Japan
9.4.2.1 Japan's Well-Established and Well-Equipped Healthcare System Ensures Demand for and Easy Access to Diagnostic Imaging
9.4.3 India
9.4.3.1 Growing Incidence of Lymphatic Filariasis is A Key Contributor to Market Growth
9.4.4 RoAPAC
9.5 Rest of the World
9.5.1 Latin America
9.5.1.1 Latin America Holds the Largest Share of the RoW Market
9.5.2 Middle East & Africa
9.5.2.1 Growing Geriatric Population & Disease Prevalence are Driving Growth in Mea

10 Competitive Landscape
10.1 Introduction
10.2 Ranking of Players, 2018
10.3 Competitive Scenario
10.4 Vendor Dive Overview
10.5 Vendor Inclusion Criteria
10.6 Vendor Dive
10.6.1 Visionary Leaders
10.6.2 Innovators
10.6.3 Dynamic Differentiators
10.6.4 Emerging Companies

11 Company Profiles
11.1 GE Healthcare
11.2 Siemens Healthineers (A Subsidiary of Siemens Group)
11.3 Philips
11.4 Canon, Inc.
11.5 Shimadzu Corporation
11.6 Stryker Corporation
11.7 Fluoptics
11.8 United Imaging Healthcare Co., Ltd.
11.9 Hitachi, Ltd.
11.10 Esaote SPA
11.11 Neusoft Corporation
11.12 Mindray Medical International Limited (A Subsidiary of Excelsior Union, Ltd.)
11.13 Mitaka Usa, Inc.
11.14 Curadel, LLC
11.15 Impedimed Limited

For more information about this report visit https://www.researchandmarkets.com/r/9uvtyf

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-lymphedema-diagnostics-market-report-2019-lymphoscintigraphy-is-rapidly-developing-to-be-the-first-line-imaging-modality-for-lymphedema-diagnostics-300951818.html

SOURCE Research and Markets